Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor NK Cells and Haplo-HCT for High-Risk Solid Tumors
NCT02100891Phase 2Terminated
- Start
- Mar 2013
- Primary completion
- Jun 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of donor natural killer cell infusion in Ewing sarcoma, neuroblastoma, rhabdomyosarcoma (RMS), osteosarcoma (OS), central nervous system tumor. Started Mar 2013; status: terminated.
02
Drugs
donor natural killer cell infusion
03
Conditions
Ewing sarcomaneuroblastomarhabdomyosarcoma (RMS)osteosarcoma (OS)central nervous system tumor
Beyond the preview
Go deeper on NCT02100891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02100891.